MX2015006324A - Metodos para la fabricacion de polipeptidos proteoliticamente procesados. - Google Patents

Metodos para la fabricacion de polipeptidos proteoliticamente procesados.

Info

Publication number
MX2015006324A
MX2015006324A MX2015006324A MX2015006324A MX2015006324A MX 2015006324 A MX2015006324 A MX 2015006324A MX 2015006324 A MX2015006324 A MX 2015006324A MX 2015006324 A MX2015006324 A MX 2015006324A MX 2015006324 A MX2015006324 A MX 2015006324A
Authority
MX
Mexico
Prior art keywords
manufacture
methods
proteolytically processed
processed polypeptides
polypeptides
Prior art date
Application number
MX2015006324A
Other languages
English (en)
Inventor
Andreas Rummel
Original Assignee
Syntaxin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntaxin Ltd filed Critical Syntaxin Ltd
Publication of MX2015006324A publication Critical patent/MX2015006324A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente invención se refiere a polipéptidos proteolíticamente activos y diversos usos de los mismos.
MX2015006324A 2012-11-21 2013-11-21 Metodos para la fabricacion de polipeptidos proteoliticamente procesados. MX2015006324A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2012/073283 WO2014079495A1 (en) 2012-11-21 2012-11-21 Methods for the manufacture of proteolytically processed polypeptides
PCT/GB2013/053072 WO2014080206A1 (en) 2012-11-21 2013-11-21 Methods for the manufacture of proteolytically processed polypeptides

Publications (1)

Publication Number Publication Date
MX2015006324A true MX2015006324A (es) 2015-09-07

Family

ID=47216287

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015002390A MX363788B (es) 2012-11-21 2012-11-21 Métodos para la producción de polipéptidos procesados proteolíticamente.
MX2015006324A MX2015006324A (es) 2012-11-21 2013-11-21 Metodos para la fabricacion de polipeptidos proteoliticamente procesados.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015002390A MX363788B (es) 2012-11-21 2012-11-21 Métodos para la producción de polipéptidos procesados proteolíticamente.

Country Status (15)

Country Link
US (4) US10087432B2 (es)
JP (3) JP6156954B2 (es)
KR (4) KR102083371B1 (es)
CN (4) CN111454931A (es)
AR (3) AR093578A1 (es)
AU (2) AU2012395188B2 (es)
BR (2) BR112015003591B1 (es)
CA (2) CA3062150C (es)
HK (1) HK1210191A1 (es)
IN (1) IN2015DN01449A (es)
MX (2) MX363788B (es)
RU (2) RU2673910C2 (es)
TW (5) TW201839134A (es)
UA (2) UA111795C2 (es)
WO (2) WO2014079495A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10792344B2 (en) * 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
KR102083371B1 (ko) * 2012-11-21 2020-03-04 입센 바이오이노베이션 리미티드 단백질 가수분해 처리된 폴리펩티드의 제조방법
WO2015088477A1 (en) * 2013-12-09 2015-06-18 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Peptide substrates recognizable by type e botulinum neurotoxin
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
US10300118B2 (en) * 2014-05-29 2019-05-28 Procell Therepautics Inc. Cell penetrating peptide, conjugate thereof with botulinum toxin, and use thereof
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
GB201607901D0 (en) * 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
EP3263710A1 (en) * 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
SI3436054T2 (sl) 2016-09-13 2022-09-30 Allergan, Inc. Stabilizirani neproteinski sestavki klostridijskih toksinov
IL273435B1 (en) * 2017-10-13 2024-01-01 Wisconsin Alumni Res Found Botulinum neurotoxin A subtype 6 and methods of pharmacological use
WO2019158745A1 (de) * 2018-02-16 2019-08-22 Bontana Therapies Gmbh Nukleinsäure-basiertes botulinum neurotoxin zur therapeutischen anwendung
KR102246906B1 (ko) * 2019-04-29 2021-04-30 주식회사 바이오셀트란 피부 또는 세포 투과능이 우수한 피부주름 방지 또는 개선용 화장료 조성물
EP4121100A2 (en) 2020-03-16 2023-01-25 Ipsen Biopharm Limited Modified botulinum neurotoxin for treating limb spasticity
GB202003813D0 (en) 2020-03-16 2020-04-29 Ipsen Biopharm Ltd Treatment of upper facial lines
GB202103372D0 (en) 2021-03-11 2021-04-28 Ipsen Biopharm Ltd Modified clostridial neurotoxins
WO2023041934A1 (en) 2021-09-16 2023-03-23 Ipsen Biopharm Limited Modified bont/a for use in the treatment of cervical dystonia
CA3228712A1 (en) 2021-09-23 2023-03-30 Nicolae GRIGORE Modified bont/a for use in the treatment of a disorder affecting an eyelid muscle of a subject
GB202113602D0 (en) 2021-09-23 2021-11-10 Ipsen Biopharm Ltd Treatment of a disorder affecting an eyelid muscle of a subject
CA3234608A1 (en) 2021-11-22 2023-05-25 Ipsen Biopharm Limited Treatment of pain
GB202206353D0 (en) 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of cervical dystonia
GB202206348D0 (en) 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of limb spasticity
GB202206361D0 (en) 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of a facial dystonia
GB202206362D0 (en) 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of upper facial lines
GB202213479D0 (en) 2022-09-14 2022-10-26 Ipsen Biopharm Ltd Cell-free clostridial neurotoxin assays

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8153397B2 (en) * 1993-09-21 2012-04-10 The United States Of America As Represented By The Secretary Of The Army Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US7214787B1 (en) * 1993-09-21 2007-05-08 United States Of America As Represented By The Secretary Of The Army Recombinant vaccine against botulinum neurotoxin
US7227010B2 (en) * 1993-09-21 2007-06-05 United States Of America As Represented By The Secretary Of The Army Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
AU2907695A (en) * 1994-08-08 1996-03-07 Wisconsin Alumni Research Foundation Purification and pharmaceutical compositions containing type g botulinum neurotoxin
US6967088B1 (en) * 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US8012491B2 (en) * 1996-08-23 2011-09-06 Syntaxin, Ltd. Recombinant toxin fragments
GB9721189D0 (en) * 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
US20040071736A1 (en) * 1998-08-25 2004-04-15 Health Protection Agency Methods and compounds for the treatment of mucus hypersecretion
DE19856897A1 (de) 1998-12-10 2000-06-15 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum zur Unterdrückung von Schnarchgeräuschen
US7740868B2 (en) * 1999-08-25 2010-06-22 Allergan, Inc. Activatable clostridial toxins
US20090018081A1 (en) * 1999-08-25 2009-01-15 Allergan, Inc. Activatable clostridial toxins
AU777556B2 (en) * 1999-08-25 2004-10-21 Allergan, Inc. Activatable recombinant neurotoxins
US20080032931A1 (en) * 1999-08-25 2008-02-07 Steward Lance E Activatable clostridial toxins
AU2001286727A1 (en) 2000-08-24 2002-03-04 Coulter Pharmaceutical, Inc. Prodrugs activated by plasmin and their use in cancer chemotherapy
TW526437B (en) * 2001-08-08 2003-04-01 Macronix Int Co Ltd Photolithography rework analysis method and system
JP2005538954A (ja) * 2002-05-31 2005-12-22 トーマス・ジェファーソン・ユニバーシティ 分子の経上皮輸送用組成物及び方法
US20040018589A1 (en) * 2002-07-25 2004-01-29 Jun Zhong Method for producing biologically active botulinum neurotoxins through recombinant DNA technique
ATE541047T1 (de) 2002-08-01 2012-01-15 Univ California Therapeutische monoklonale antikörper zur neutralisierung von botulinum neurotoxinen
AU2003272800A1 (en) * 2002-10-01 2004-04-23 University Of Maryland Methods for identifying inhibitors of botulinum neurotoxins
WO2005030119A2 (en) * 2003-04-11 2005-04-07 Allergan, Inc. Botulinum toxin a peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy
US20080171347A1 (en) 2003-04-11 2008-07-17 Atassi M Zouhair Determining and reducing immunoresistance to botulinum toxin therapy using botulinum toxin a peptides
WO2005035730A2 (en) * 2003-10-07 2005-04-21 Allergan, Inc. Dna sequences of the botulinum neurotoxin complex of type a-hall (allergan) strain
US7172764B2 (en) * 2003-11-17 2007-02-06 Allergan, Inc. Rescue agents for treating botulinum toxin intoxications
US7811584B2 (en) * 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
CA2575994A1 (en) * 2004-08-04 2006-02-16 Allergan, Inc. Optimizing expression of active botulinum toxin type a
ATE416191T1 (de) * 2004-09-01 2008-12-15 Allergan Inc Abbaubare clostridientoxine
DE102004043009A1 (de) * 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
GB0426397D0 (en) * 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US8399400B2 (en) * 2004-12-01 2013-03-19 Syntaxin, Ltd. Fusion proteins
GB0426394D0 (en) * 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US7659092B2 (en) * 2004-12-01 2010-02-09 Syntaxin, Ltd. Fusion proteins
DE102005002978B4 (de) * 2005-01-21 2013-04-25 Merz Pharma Gmbh & Co. Kgaa Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form
EP2316847A3 (en) * 2005-03-15 2012-01-18 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
US8021859B2 (en) * 2005-03-15 2011-09-20 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
US7465457B2 (en) * 2005-04-14 2008-12-16 Wisconsin Alumni Research Foundation Method for preparing botulinum neurotoxin type A light chain
DE102005019302A1 (de) * 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
ES2341892T5 (es) * 2005-09-19 2019-03-27 Allergan Inc Toxina clostridial activable por toxinas clostridiales
US9072735B2 (en) 2005-10-03 2015-07-07 Yong Qian Proteinases destroy cancer tumor's solid structure and kill cancer cells locally
US7464917B2 (en) * 2005-10-07 2008-12-16 Appiled Materials, Inc. Ampoule splash guard apparatus
DE102005051789B4 (de) * 2005-10-28 2014-08-07 Toxogen Gmbh Der Botulinus Neurotoxin A Proteinrezeptor und seine Anwendungen
GB0610867D0 (en) * 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
US7993656B2 (en) * 2006-07-11 2011-08-09 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
KR100677871B1 (ko) * 2006-09-11 2007-02-02 주식회사 메가젠 골충진재 성형 장치 및 골충진재 성형 방법
WO2008152429A1 (en) * 2007-06-14 2008-12-18 Health Protection Agency Chemically modified peptides with improved immunogenicity
EP2178905B1 (en) * 2007-07-26 2013-11-06 Allergan, Inc. Methods of activiting clostridial toxins
EP2023327A1 (en) * 2007-07-27 2009-02-11 Foxboro Eckardt Gmbh Operation voltage controller and method for controlling an operation voltage controller
EP2214696A1 (en) * 2007-10-23 2010-08-11 Allergan, Inc. Methods of treating chronic neurogenic inflammation using modified clostridial toxins
KR20100087019A (ko) * 2007-10-23 2010-08-02 알러간, 인코포레이티드 변형 클로스트리듐 독소를 사용한 비뇨생식기-신경학적 질환의 치료 방법
PT2271670E (pt) * 2008-03-14 2014-11-28 Allergan Inc Ensaio imunobaseado da atividade do serotipo a da toxina botulínica
EP2313434A4 (en) 2008-07-31 2013-03-27 Univ California NEUTRALIZING ANTIBODIES OF BOTULINIC NEUROTOXINS
WO2010085473A1 (en) * 2009-01-20 2010-07-29 Trustees Of Tufts College Methods for the delivery of toxins or enzymatically active portions thereof
RU2571212C2 (ru) * 2009-02-19 2015-12-20 Мерц Фарма Гмбх Унд Ко. Кгаа Средства и способы получения высокоочищенного нейротоксина
KR20200146046A (ko) * 2009-03-13 2020-12-31 알러간, 인코포레이티드 면역 기반 보툴리눔 독소 혈청형 ａ 활성 검정에 유용한 세포
BRPI1015311B1 (pt) * 2009-04-27 2024-01-09 Merz Pharma Gmbh & Co. Kgaa Método para determinar a quantidade de polipeptídeo de neurotoxina processada em uma solução, dispositivo para determinação da quantidade de polipeptídeo de neurotoxina processada contida em uma solução e kit adaptado
US20100303757A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Interleukin Retargeted Endopepidases
US20100303783A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Tachykinin Retargeted Endopepidases
CA2763692A1 (en) * 2009-07-02 2011-01-06 Merz Pharma Gmbh & Co. Kgaa Neurotoxins exhibiting shortened biological activity
WO2011047265A1 (en) * 2009-10-16 2011-04-21 Biosentinel, Inc. Resonance energy transfer assay with synaptobrevin substrate moiety
US10246492B2 (en) * 2009-10-16 2019-04-02 Biomadison, Inc. Botulinum assay with synaptobrevin substrate moiety
RU2012129557A (ru) * 2009-12-16 2014-01-27 Аллерган, Инк. МОДИФИЦИРОВАННЫЕ ТОКСИНЫ Clostridial, СОДЕРЖАЩИЕ ИНТЕГРИРОВАННЫЙ САЙТ-СВЯЗЫВАЮЩИЙ ДОМЕН ПРОТЕАЗНОГО РАСЩЕПЛЕНИЯ
US20130245227A1 (en) * 2010-01-15 2013-09-19 Allergan, Inc. Methods of activating clostridial toxins
PL2684890T3 (pl) * 2010-01-25 2016-11-30 Metody wewnątrzkomórkowego przekształcania białek jednołańcuchowych w ich formę dwułańcuchową
AT511002A1 (de) * 2011-02-08 2012-08-15 Univ Innsbruck Verfahren zur verformung von cellulosecarbamat und produkte, die nach diesem verfahren hergestellt werden
WO2012112432A1 (en) * 2011-02-14 2012-08-23 Allergan, Inc. Methods of inhibiting aberrant blood vessel formation using opioid retargeted endopeptidases
US20120207734A1 (en) * 2011-02-14 2012-08-16 Allergan, Inc. Methods of Inhibiting Aberrant Blood Vessel Formation Using Opioid Retargeted Endpeptidases
GB201108108D0 (en) * 2011-05-16 2011-06-29 Syntaxin Ltd Therapeutic fusion proteins
EP2677029B1 (en) * 2011-05-19 2017-05-10 Ipsen Bioinnovation Limited Methods for the manufacture of proteolytically processed polypeptides
JP6162135B2 (ja) * 2011-11-09 2017-07-12 メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー 短縮された生物活性を示す神経毒
JP2015509372A (ja) * 2012-03-07 2015-03-30 メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー 修飾ルシフェラーゼに基づいて神経毒活性を測定するための手段および方法
KR101729710B1 (ko) * 2012-04-09 2017-04-24 서울대학교산학협력단 물에 안정하게 분산되는 멜라닌 나노입자를 포함하는 핵자기 공명 영상 조영제
WO2013180799A1 (en) * 2012-05-30 2013-12-05 President And Fellows Of Harvard College Engineered botulinum neurotoxin
US20150232828A1 (en) * 2012-08-20 2015-08-20 Merz Pharma Gmbh & Co. Kgaa Method for the manufacturing of recombinant proteins harbouring an n-terminal lysine
KR102083371B1 (ko) * 2012-11-21 2020-03-04 입센 바이오이노베이션 리미티드 단백질 가수분해 처리된 폴리펩티드의 제조방법
ES2618800T3 (es) * 2012-11-22 2017-06-22 Sanofi Método para preparar derivados de feniloximetil-nitro-imidazol y uso de los mismos
GB201407525D0 (en) 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
CA2969463A1 (en) * 2014-12-09 2016-06-16 New York University Clostridial neurotoxin fusion proteins, propeptide fusions, their expression, and use
EP3270951B1 (en) * 2015-03-16 2020-09-09 California Institute of Technology Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making
GB201505306D0 (en) * 2015-03-27 2015-05-13 Ipsen Biopharm Ltd Chimeric polypeptides
GB201607901D0 (en) * 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
CA3024331A1 (en) * 2016-05-16 2017-11-23 President And Fellows Of Harvard College Method for purification and activation of botulinum neurotoxin
EP4212545A1 (en) * 2016-07-08 2023-07-19 Children's Medical Center Corporation A novel botulinum neurotoxin and its derivatives

Also Published As

Publication number Publication date
CN112048009A (zh) 2020-12-08
KR20180077343A (ko) 2018-07-06
CA3062150C (en) 2021-12-21
KR102083371B1 (ko) 2020-03-04
JP2019030333A (ja) 2019-02-28
RU2015124069A (ru) 2017-01-10
AR093578A1 (es) 2015-06-10
US10087432B2 (en) 2018-10-02
AU2017221793A1 (en) 2017-09-21
CN111454931A (zh) 2020-07-28
MX2015002390A (es) 2015-08-05
AU2012395188A2 (en) 2015-04-09
AU2012395188B2 (en) 2017-06-01
KR20150085844A (ko) 2015-07-24
JP2015536654A (ja) 2015-12-24
UA117231C2 (uk) 2018-07-10
JP2015536644A (ja) 2015-12-24
CN104797595A (zh) 2015-07-22
RU2015107240A (ru) 2016-09-27
TWI713862B (zh) 2020-12-21
US20190100739A1 (en) 2019-04-04
US20200339971A1 (en) 2020-10-29
TW201839135A (zh) 2018-11-01
JP6156954B2 (ja) 2017-07-05
TW201839133A (zh) 2018-11-01
TW201839134A (zh) 2018-11-01
UA111795C2 (uk) 2016-06-10
BR112015003591B1 (pt) 2022-02-01
BR112015003591A8 (pt) 2018-01-02
TW201839132A (zh) 2018-11-01
MX363788B (es) 2019-04-03
CA2880897A1 (en) 2014-05-30
RU2673910C2 (ru) 2018-12-03
HK1210191A1 (en) 2016-04-15
CA3062150A1 (en) 2014-05-30
KR20150041790A (ko) 2015-04-17
US20230015772A1 (en) 2023-01-19
WO2014079495A1 (en) 2014-05-30
TWI709649B (zh) 2020-11-11
US10808236B2 (en) 2020-10-20
BR112015003591A2 (es) 2015-02-20
BR112015010550A2 (pt) 2017-08-22
US20150225709A1 (en) 2015-08-13
CA2880897C (en) 2020-01-14
KR20170059007A (ko) 2017-05-29
CN104870468A (zh) 2015-08-26
IN2015DN01449A (es) 2015-07-03
KR102083373B1 (ko) 2020-03-03
AR118019A2 (es) 2021-09-08
TW201439322A (zh) 2014-10-16
US11441141B2 (en) 2022-09-13
BR112015010550A8 (pt) 2018-01-02
WO2014080206A1 (en) 2014-05-30
AU2012395188A1 (en) 2015-03-05
CN104797595B (zh) 2021-01-29
AR127620A2 (es) 2024-02-14
CN104870468B (zh) 2020-11-10
AU2017221793B2 (en) 2019-05-16

Similar Documents

Publication Publication Date Title
MX2015006324A (es) Metodos para la fabricacion de polipeptidos proteoliticamente procesados.
MX2022000026A (es) Anticuerpos para tau.
PH12014501427B1 (en) Anti-phf-tau antibodies and their uses
IN2014DN08721A (es)
IN2015DN00127A (es)
MX2013015311A (es) Polipeptidos de enlace de pcsk9 y metodos de uso.
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
IN2014DN08481A (es)
MX2016004945A (es) Procesos para la preparacion de compuestos plaguicidas.
PH12014501605A1 (en) Anti-lrp5 antibodies and methods of use
IN2012MU03723A (es)
IN2014DN06104A (es)
IN2014DN09450A (es)
MX369662B (es) Granulos de harina de microalgas y proceso de preparacion de estos.
IN2013MU00848A (es)
IN2013MU03641A (es)
MX358132B (es) Solucion de trombina y metodos de uso de esta.
MX2015016603A (es) Composiciones de corticosteroides.
IN2013MU01113A (es)
UA117567C2 (uk) Композиція, яка стимулює лактацію, на основі фосфатидилсерину
IN2014DN10209A (es)
IN2014DN07191A (es)
MY167578A (en) Novel cheese and method for producing the same
IN2014DN11218A (es)
WO2013181572A3 (en) Methods related to panitumumab